Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
5(83%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_1
2
33%
Ph phase_3
1
17%
Ph phase_2
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Recruiting3
Active, not recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)

Trials by Status

active_not_recruiting233%
recruiting350%
completed117%

Recent Activity

5 active trials
Showing 5 of 6
recruiting

Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County

NCT07467018
recruitingphase_1

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

NCT06819176
recruitingphase_2

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

NCT06532656
active_not_recruitingphase_3

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808
active_not_recruitingphase_2

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07467018

Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County

Recruiting
NCT06819176Phase 1

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

Recruiting
NCT06532656Phase 2

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

Recruiting
NCT06333808Phase 3

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Active Not Recruiting
NCT05502341Phase 2

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

Active Not Recruiting
NCT03739866Phase 1

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6